[go: up one dir, main page]

EA200870599A1 - Стабильные препараты лаквинимода - Google Patents

Стабильные препараты лаквинимода

Info

Publication number
EA200870599A1
EA200870599A1 EA200870599A EA200870599A EA200870599A1 EA 200870599 A1 EA200870599 A1 EA 200870599A1 EA 200870599 A EA200870599 A EA 200870599A EA 200870599 A EA200870599 A EA 200870599A EA 200870599 A1 EA200870599 A1 EA 200870599A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lakvinimoda
stable preparations
pharmaceutically acceptable
preparations
stable
Prior art date
Application number
EA200870599A
Other languages
English (en)
Other versions
EA018031B1 (ru
Inventor
Шуламит Паташник
Даниэлла Личт
Адриан Гилберт
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA200870599A1 publication Critical patent/EA200870599A1/ru
Publication of EA018031B1 publication Critical patent/EA018031B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции, содержащей фармацевтически приемлемую соль N-этил-N-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамида, N-метилглюкамин и фармацевтически приемлемый носитель.
EA200870599A 2006-06-12 2007-06-12 Стабильные препараты лаквинимода EA018031B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
PCT/US2007/013721 WO2007146248A2 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Publications (2)

Publication Number Publication Date
EA200870599A1 true EA200870599A1 (ru) 2009-06-30
EA018031B1 EA018031B1 (ru) 2013-05-30

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870599A EA018031B1 (ru) 2006-06-12 2007-06-12 Стабильные препараты лаквинимода

Country Status (27)

Country Link
US (3) US7989473B2 (ru)
EP (1) EP2035001B1 (ru)
JP (1) JP5226678B2 (ru)
KR (4) KR20150065951A (ru)
CN (1) CN101466379B (ru)
AR (1) AR061348A1 (ru)
AT (1) ATE532515T1 (ru)
AU (1) AU2007258366B2 (ru)
BR (1) BRPI0713694A2 (ru)
CA (2) CA2654982C (ru)
CY (1) CY1113003T1 (ru)
DK (1) DK2035001T3 (ru)
EA (1) EA018031B1 (ru)
ES (1) ES2377149T3 (ru)
HR (1) HRP20120093T1 (ru)
IL (1) IL195724A (ru)
MX (1) MX2008015808A (ru)
NO (1) NO342485B1 (ru)
NZ (1) NZ573846A (ru)
PL (1) PL2035001T3 (ru)
PT (1) PT2035001E (ru)
RS (1) RS52169B (ru)
SI (1) SI2035001T1 (ru)
TW (1) TWI400073B (ru)
UA (1) UA96449C2 (ru)
WO (1) WO2007146248A2 (ru)
ZA (1) ZA200810790B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SI1937642T1 (sl) 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
TWI400073B (zh) 2006-06-12 2013-07-01 Teva Pharma 穩定之拉癸利莫（ｌａｑｕｉｎｉｍｏｄ）製劑
ES2445451T3 (es) * 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
NZ591315A (en) * 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
MX2011013902A (es) * 2009-06-19 2012-02-23 Teva Pharma Tratamiento de esclerosis multiple con laquinimod.
CN102480960A (zh) * 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
SI2467372T1 (sl) 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
EA201290859A1 (ru) * 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение люпус-артрита с использованием лаквинимода
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
BR112012022187A2 (pt) * 2010-03-03 2015-09-22 Teva Pharma tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
EA201390074A1 (ru) * 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
US8580819B2 (en) 2010-07-09 2013-11-12 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2014001050A (es) * 2011-07-28 2014-04-14 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
MX2014001048A (es) * 2011-07-28 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimo de interferon-beta.
AU2012322706A1 (en) * 2011-10-12 2014-05-22 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
HK1198296A1 (en) 2012-02-16 2015-03-27 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN104955522A (zh) 2012-11-07 2015-09-30 梯瓦制药工业有限公司 拉喹莫德胺盐
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治療多發性硬化症
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤
KR20150143499A (ko) * 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법
CN105848653A (zh) * 2013-09-27 2016-08-10 梯瓦制药工业有限公司 用于治疗多发性硬化症的拉喹莫德联合治疗
EP3082814A4 (en) * 2013-12-20 2017-06-21 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay huntington's disease progression
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
AU775995B2 (en) 1999-06-07 2004-08-19 Nycomed Gmbh Novel preparation and administration form comprising an acid-labile active compound
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SI1937642T1 (sl) 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
TWI400073B (zh) 2006-06-12 2013-07-01 Teva Pharma 穩定之拉癸利莫（ｌａｑｕｉｎｉｍｏｄ）製劑
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
ES2445451T3 (es) 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
NZ591315A (en) 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
MX2011013902A (es) 2009-06-19 2012-02-23 Teva Pharma Tratamiento de esclerosis multiple con laquinimod.
CN102480960A (zh) 2009-07-30 2012-05-30 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
SI2467372T1 (sl) 2009-08-10 2016-09-30 Teva Pharmaceutical Industries Ltd. Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
EA201290859A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение люпус-артрита с использованием лаквинимода
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
BR112012022187A2 (pt) 2010-03-03 2015-09-22 Teva Pharma tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
EA201390074A1 (ru) 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
US8580819B2 (en) 2010-07-09 2013-11-12 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

Also Published As

Publication number Publication date
US8383645B2 (en) 2013-02-26
EA018031B1 (ru) 2013-05-30
WO2007146248A3 (en) 2008-12-24
KR20090017694A (ko) 2009-02-18
TW200815006A (en) 2008-04-01
JP5226678B2 (ja) 2013-07-03
IL195724A (en) 2015-09-24
PT2035001E (pt) 2012-02-06
TWI400073B (zh) 2013-07-01
AU2007258366A1 (en) 2007-12-21
CY1113003T1 (el) 2016-04-13
PL2035001T3 (pl) 2012-05-31
AU2007258366B2 (en) 2012-10-25
KR20150065951A (ko) 2015-06-15
NO342485B1 (no) 2018-05-28
SI2035001T1 (sl) 2012-03-30
US20120302600A1 (en) 2012-11-29
DK2035001T3 (da) 2012-02-27
KR101495327B1 (ko) 2015-02-24
ES2377149T3 (es) 2012-03-22
US7989473B2 (en) 2011-08-02
HK1121971A1 (en) 2009-05-08
CA2654982C (en) 2015-11-10
CA2899472C (en) 2019-04-30
EP2035001A2 (en) 2009-03-18
CA2654982A1 (en) 2007-12-21
CN101466379B (zh) 2012-10-31
KR20140091778A (ko) 2014-07-22
CA2899472A1 (en) 2007-12-21
CN101466379A (zh) 2009-06-24
IL195724A0 (en) 2009-09-01
ZA200810790B (en) 2010-03-31
MX2008015808A (es) 2009-02-17
US20070293537A1 (en) 2007-12-20
WO2007146248A2 (en) 2007-12-21
AR061348A1 (es) 2008-08-20
RS52169B (en) 2012-08-31
HRP20120093T1 (hr) 2012-03-31
ATE532515T1 (de) 2011-11-15
EP2035001B1 (en) 2011-11-09
NZ573846A (en) 2012-01-12
BRPI0713694A2 (pt) 2012-10-30
JP2009539984A (ja) 2009-11-19
US20110251235A1 (en) 2011-10-13
NO20090175L (no) 2009-03-11
KR20160013273A (ko) 2016-02-03
EP2035001A4 (en) 2009-09-23
UA96449C2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
EA200870599A1 (ru) Стабильные препараты лаквинимода
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200901319A1 (ru) Композиции для назального введения
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA200970156A1 (ru) Пиридизиноновые производные
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA201170441A1 (ru) Терапевтические противовирусные пептиды
MX358617B (es) Formulaciones de inhibidores de dpp iv.
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA200870545A1 (ru) Новые гетероциклические соединения
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
EA201100286A1 (ru) Композиция кветиапина
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201290229A1 (ru) Производные спиролактама и их применение

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU